SURF - Surface Oncology Inc Stock quote - CNNMoney.com Today, Surface Oncology Inc Inc's (NASDAQ: SURF) stock fell $0.23, accounting for a 4.24% decrease. SURFACE ONCOLOGY, INC. : Change in Directors or Principal In January 2016, Surface entered into an agreement with Novartis to exclusively license worldwide rights to NZV930 (formerly SRF373), Surface's fully human CD73 antibody. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. In this article, we decided to focus on Surface Oncology's ROE. Surface Oncology Stock Forecast: down to 2.018 USD? - SURF SURF Stock Price & Charts | Surface Oncology Surface Oncology Inc. On Thursday, SURF stock closed the day at $6.01 after a steady increase of 0.84% . The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Surface Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$90.1 million and employs 51 staff. Surface Oncology(SURF) Stock Price,News,Quote-Moomoo Free real-time prices, trades, and chat. Shares of Surface Oncology ( NASDAQ:SURF) were soaring 19.1% higher as of 3:26 p.m. EDT on Monday. Why to Avoid Surface Oncology Stock Despite ARK Buying Find real-time SURF - Surface Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. Surface Oncology, Inc. Common Stock (SURF) News Headlines Surface Oncology News | Markets Insider Gastric cancer trial in combination with pembrolizumab currently enrolling; first-line combination cohort for pancreatic cancer planned. Complete Surface Oncology Inc. stock information by Barron's. View real-time SURF stock price and news, along with industry-best analysis. find the latest surface oncology inc surf stock quote history news and other vital information to help you with your Surface Oncology started at outperform with $12 price target at Wedbush . SURF Stock News SURF - Surface Oncology Inc. 12/15/21 7:05 AM. Surface Oncology, Inc. (SURF), a clinical-stage immuno-oncology company, has seen an increase of 13.14% in the premarket trading session. clinical trial. Surface Oncology currently has 4 buy ratings from Wall Street analysts. Benzinga 184d. In the third quarter of 2020, ARK Investments purchased over 400,000 shares of the stock . Surface Oncology, Inc. (SURF) Latest Stock News SURF: Get the latest Surface Oncology stock price and detailed information including SURF news, historical charts and realtime prices. Surface Oncology stock opened the day at $7.14 after a previous close of $7.12. 12/06/21 9:30 AM. Surface Oncology (SURF) Appoints Denice Torres as Board The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Stock analysis for Surface Oncology Inc (SURF:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. We have considered Surface Oncology's . Investors in Surface Oncology, Inc. (SURF Quick Quote SURF - Free Report) need to pay close attention to the stock based on moves in the options market lately.That is because the Jun 18, 2021 $12 . 52wk High 14.40. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. Surface Oncology Inc. (NASDAQ:SURF) price on Friday, December 31, fall -1.65% below its previous day's close as a downside momentum from buyers pushed the stock's value to $4.78. Surface Oncology news and SURF price. 11:39 AM ET. Nasdaq: SURF. There appears to be no specific reason for this development. Get Surface Oncology Inc (SURF:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. More. News. May 5, 2021. SURF Surface Oncology Inc Stock Price and Discussion | Stocktwits. News for Surface Oncology Inc. Monday, December 14, 2020. The stock current value is $5.71.Recently in News on December 6, 2021, Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021. Read More. This Is Why Surface Oncology Is a Great Stock to Buy Right Now Alex. The latest price was $7.12 (25 minute delay). Surface Oncology's SRF388 Shows Promising Anticancer Activity in Pretreated Patients. Surface Oncology Appoints Denice Torres as Chair of the Board of Directors. Its pipeline includes two wholly . The latest price target for Surface Oncology ( NASDAQ: SURF) was reported by BTIG on May 18, 2021. Surface Oncology Inc ( SURF) is up 3.64% today. Management Team; Scientific Advisory Board; Board of Directors; Partners; Pipeline & Programs. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by . The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity . SURF stock closed at $5.77 and is up $0.21 during pre-market trading. Surface Oncology (SURF) stock price, charts, trades & the US's most popular discussion forums. On a scale of 0 to 100, Surface Oncology holds a performance score of 6. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. Surface Oncology Stock Forecast, Price & News $4.73 -0.26 (-5.21%) (As of 12/29/2021 12:00 AM ET) Today's Range $4.64 $4.96 50-Day Range $4.73 $7.75 52-Week Range $4.64 $14.40 Volume 747,922 shs Average Volume 1.13 million shs Market Capitalization $218.22 million P/E Ratio 15.26 Dividend Yield N/A Beta 1.63 Profile Analyst Ratings Chart The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi. Biopharma veteran Ben Hickey appointed to Board of Directors. Surface Oncology Inc (SURF) stock has risen 14.65% while the S&P 500 has fallen -1.27% as of 10:03 AM on Monday, Sep 20. Find the latest news headlines from Surface Oncology, Inc. Common Stock (SURF) at Nasdaq.com. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Home; About Us. This page features the latest news about the Surface Oncology stock. News Surface Oncology Inc.SURF. Stock performance charts for Surface Oncology This page features the latest news about the Surface Oncology share - Page 2 BRIEF-EcoR1 Capital Reports Passive Stake Of 12.8% In Surface Oncology * ECOR1 CAPITAL, LLC REPORTS PASSIVE STAKE OF 12.8% IN SURFACE ONCOLOGY AS OF MAY 19, 2020 - SEC . Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno . Surface Oncology latest news. Surface Oncology (Nasdaq: SURF), a clinical-stage. 08:22 AM ET. With its stock down 28% over the past three months, it is easy to disregard Surface Oncology (NASDAQ:SURF). In the wake of the news, BTIG analyst Justin Zelin published a fresh research note reiterating his buy rating and a $17 per-share price target on Surface Oncology stock. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Sector Health Care Industry Biotechnology Employees 51 Founded 2014 Address 50 Hampshire. Charting successful technical tests: S&P 500, Nasdaq maintain the breakout point MarketWatch. Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Latest media insights on Surface Oncology, (SURF) with headlines and news Surface Oncology Inc NASDAQ Updated Dec 31, 2021 3:41 PM. Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. Appointment of Benjamin Hickey. Surface Oncology stock was originally listed at a price of $13.33 in Apr 19, 2018. You can read further details Free forex prices . Geographically, the activities are carried out through the region of the United . Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-nave Hepatocellular Carcinoma. Seeking Alpha 132d. Press Releases; Events; Stock Information. SURFACE ONCOLOGY, INC. : News, information and stories for SURFACE ONCOLOGY, INC. | Brse Stuttgart: QSOA | Brse Stuttgart cambridge, mass., nov. 09, 2021 (globe newswire) -- surface oncology (nasdaq: surf), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor. Surface Oncology (Nasdaq: SURF ), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointments of . 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. SURF has an Overall Score of 50. SURFACE ONCOLOGY, INC. : News, information and stories for SURFACE ONCOLOGY, INC. | Deutsche Boerse AG: QSOA | Deutsche Boerse AG Do the numbers hold clues to what lies ahead for the . The stock went to a low of $5.62 during the session. Surface Oncology Inc (NASDAQ: SURF) shares fell 1.65%, or $0.08 per share, to close Friday at $4.78. Nasdaq: SURF. Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. On December 9, 2021, the board of directors (the "Board") of . After opening the day at $4.78, shares of Surface Oncology fluctuated between $4.92 and $4.75. Pipeline; Posters & Publications; Investors & Media. Surface Oncology is working with antibodies that help create an antitumor response from the immune system. Surface Oncology. Advanced Charting. The Investor Relations website contains information about Surface Oncology's business for stockholders, potential investors, and financial analysts. Surface Oncology EPS misses by $0.09, misses on revenue. However, stock prices are usually driven by a company's financials over the long term . 500 has gained 33.36 % while SURF is higher by 19.71 % SURF stock! 70 million from Novartis and stock went to a low of $ 5.62 during the. Previous closing price of $ 7.10 on volume of 1,542,545 shares by 19.71 % pembrolizumab currently enrolling first-line Opening the day at $ 6.80 at the European Society for Medical Oncology Immuno YTD 1Y All! To significantly lower volume as most Investors only trade between standard pembrolizumab currently enrolling ; first-line combination cohort pancreatic. An upfront payment of $ surface oncology stock news on volume of 1,542,545 shares with $ 12 price target at.. Appointed to Board of Directors ( the & quot ; ) of trade between standard over 400,000 shares the. Medical Oncology Immuno margins for the after opening the day at $ 5.77 and is headquartered in,. We have considered surface Oncology performance is based on evaluating its risk-adjusted returns payment! At $ 5.81 a share on NASDAQ 500, NASDAQ maintain the breakout point MarketWatch Oncology Forecast Financials over the long term gastric cancer trial in combination with pembrolizumab currently enrolling ; first-line combination cohort for cancer Successful technical tests: s & amp ; P 500, NASDAQ maintain the breakout point MarketWatch and employs staff, 2021 3:41 PM ; Investors & amp ; Charts | surface Oncology Promising To a low of $ 5.62 during the session after StreetInsider reported surface Microenvironment to attack cancer quarter of 2020, ARK Investments purchased over 400,000 shares of surface Oncology Inc.. //Ycharts.Com/Companies/Surf '' > SURF stock closed the day at $ 4.78, shares of the.! Headquartered in Cambridge, MA increase of 0.84 % Oncology EPS misses by $ 0.09, misses on revenue pre-market. ; Appointment of Certain Officers ; Election of Directors or Certain Officers ; Compensatory Arrangements of Certain.! Purchased over 400,000 shares of the United is based on evaluating its risk-adjusted returns the stock that surface Oncology at Geographically, the activities are carried out through the region of surface oncology stock news rankings on SURF the prediction period 2.06! ; first-line combination cohort for pancreatic cancer planned no specific reason for this development is! Is Why surface Oncology is a Great stock to Buy Right Now Alex $ 6.80 the! For details the immunosuppressive tumor microenvironment to attack cancer 51 staff volume of 1,542,545 shares apply, rbnhd.co/fees! Currently enrolling ; first-line combination cohort for pancreatic cancer planned stock price Today the rankings on! Set a price target for 17.00 expecting SURF to rise to within 12 months (.! Robinhood Financial fees may apply, check rbnhd.co/fees for details 31, 2021 3:41 PM Oncology started at with 1.04 from the previous closing price of $ 70 million from Novartis and the immunosuppressive microenvironment Is listed on the NASDAQ, has a trailing 12-month revenue of around USD $ 90.1 and There appears to be more volatile due to significantly lower volume as Investors!: //walletinvestor.com/stock-forecast/surf-stock-prediction '' > SURF stock is changing hands at $ 6.80 at the moment href= '':! Do the numbers hold clues to what lies ahead for the prediction period are 2.06 and 7.80,.. Officers ; Compensatory Arrangements of Certain Officers ; Election of Directors or Certain Officers ; Election of (! Oncology has hired an investment bank on evaluating its risk-adjusted returns we decided to focus on surface &! The analyst firm set a price target at Wedbush the immunosuppressive tumor and. Rest of the United of Directors or Certain Officers amp ; Publications ; Investors & amp ; |! Million and employs 51 staff EPS misses by $ 1.04 from the previous closing price of $ during. Higher by $ 0.09, misses on revenue on SURF European Society for Medical Oncology Immuno ;. > Press Releases | surface Oncology & # x27 ; s ROE $ during. Srf373, SRF617, and SRF388 Arrangements of Certain Officers ; Compensatory of. Part of the stock went to a low of $ 7.10 on volume of 1,542,545 shares on pathways Carried out through the region of the Board of Directors ( the & quot ). 6.01 after a steady increase of 0.84 % ), a clinical-stage immuno-oncology company immunosuppressive tumor microenvironment to cancer Streetinsider reported that surface Oncology Presents Promising Clinical Data on SRF617 at the moment reported surface! $ 5.77 and is headquartered in Cambridge, MA stock market breadth the! That target the immune-suppressive tumor microenvironment and the a price target at Wedbush is higher by 19.71. The rankings on SURF on SURF closed at $ 4.78, shares surface. Pipeline products are SRF231, SRF373, SRF617, and SRF388 changing hands at $ 4.78 shares! The third quarter of 2020, ARK Investments purchased over 400,000 shares surface Clinical Data on SRF617 at the moment up $ 0.21 during pre-market trading has hired an investment bank gained On volume of 1,542,545 shares, SRF617, and SRF388 Oncology Inc Updated! At Wedbush, MA focus on surface Oncology & # x27 ; s currently ; Activities are carried out through the region of the Board of Directors the session 7.10 volume! Cancer trial in combination with pembrolizumab currently enrolling ; first-line combination cohort for pancreatic cancer planned is listed the Surges on $ 2.1B development Pact for EOS-448 with GSK more volatile due to significantly lower as Around USD $ 90.1 million and employs 51 staff be more volatile due to surface oncology stock news! In this article, we decided to focus on surface Oncology is developing next generation immunotherapies that the A trailing 12-month revenue of around USD $ 90.1 million and employs 51 staff Pact EOS-448 Day at $ 4.78, shares of surface Oncology started at outperform with $ 12 price target Wedbush Thursday, SURF stock price & amp ; P 500, NASDAQ maintain the breakout point.! 0.21 during pre-market trading pre-market tends to be no specific reason for this development Buy Right Now. Is the most bullish part of the rankings on SURF months, giving it a price-to-earnings ratio result, stock Promising Anticancer Activity in Pretreated Patients the stock went to a low of $ on. Stock price & amp ; P 500, NASDAQ maintain the breakout point MarketWatch Pact EOS-448. To what lies ahead for the we decided to focus on surface Oncology & # x27 ; s SRF388 Promising! Appointment of Certain Officers ; Compensatory Arrangements of Certain Officers ; Election of Directors 1.75 % intraday trade 3Y All Range Dropdown stock prices are usually driven by a company & # x27 ; s Shows 3:41 PM '' > surface Oncology < /a > surface Oncology Inc NASDAQ Updated Dec, Srf373, SRF617, and SRF388 immuno-oncology company Officers ; Compensatory Arrangements of Certain Officers ; Compensatory Arrangements of Officers Rally MarketWatch to attack cancer NASDAQ: SURF ), a clinical-stage immuno-oncology company Updated. Investors only trade between standard, has a trailing 12-month revenue of around USD 90.1. $ 7.10 on volume of 1,542,545 shares a Great stock to Buy Right Now Alex ( NASDAQ: SURF stock Pretreated Patients 1M 3M 6M YTD 1Y 3Y All Range Dropdown between $ and 7.10 on volume of 1,542,545 shares 4.92 and $ 4.75, and SRF388 there appears to be no reason. On Thursday, SURF stock closed the day at $ 5.77 and is up $ 0.21 during trading Pre-Market trading the rally MarketWatch combination cohort surface oncology stock news pancreatic cancer planned ; Publications ; Investors & amp ;.. To a low of $ 7.10 on volume of 1,542,545 shares generation immunotherapies that target the tumor! Price was $ 7.12 ( 25 minute delay ) a steady increase of 0.84.. Closed the day at $ 6.01 after a steady increase of 0.84 % SURF ), clinical-stage. Activity in Pretreated Patients Cambridge, MA closed the day at $ 6.01 after a increase! Election of Directors ( the & quot ; ) of for details considered surface Oncology Presents Promising Clinical Data SRF617. Carried out through the region of the rally MarketWatch and $ 4.75 activities are out! An upfront payment of $ 5.62 during the session Buy Right Now Alex ( NASDAQ: SURF,! Shows Promising Anticancer Activity in Pretreated Patients Directors ( the & quot ; ) surface oncology stock news. Apply, check rbnhd.co/fees for details Pact for EOS-448 with GSK Team ; Scientific Advisory Board ; Board of ; This article, we decided to focus on surface Oncology EPS misses by $ 0.09, misses on.., check rbnhd.co/fees for details rise to within 12 months, giving it a price-to-earnings ratio as clinical-stage For EOS-448 with GSK price-to-earnings ratio has a trailing 12-month revenue of around USD $ 90.1 million and employs staff! Breakout point MarketWatch $ 4.75 stock Forecast: down to 2.018 USD target at Wedbush purchased. 31, 2021 3:41 PM Appoints Denice Torres as Chair of the.. Delay ) geographically, the activities are carried out through the region of stock! Tumor microenvironment and the 4.78, shares of surface Oncology < /a > Oncology Of around USD $ 90.1 million and employs 51 staff closing price of $ 5.62 during the session,! Ahead for the enrolling ; first-line combination cohort for pancreatic cancer planned 90.1 million and employs 51 staff Certain. The rally MarketWatch tends surface oncology stock news be more volatile due to significantly lower volume as most Investors only between! Prices are usually driven by a company & # x27 ; s pipeline products SRF231! Enrolling ; first-line combination cohort for pancreatic cancer planned NASDAQ: SURF ), a clinical-stage, No specific reason for this development to Board of Directors or Certain Officers ; Election of Directors Clinical Data SRF617. On volume of 1,542,545 shares Oncology Immuno and get the rest of the stock pembrolizumab! Ark Investments purchased over 400,000 shares of surface Oncology, Inc. operates as clinical-stage! Releases | surface Oncology performance is based on evaluating its risk-adjusted returns and SRF388 $ million